GH
A regulatory green light, and not the boring kind
Guardant Health says the FDA approved its Guardant360 CDx test as a companion diagnostic for Boehringer Ingelheim’s HERNEXEOS, a targeted therapy for adults with HER2-mutant advanced non-small cell lung cancer. In plain English: if a doctor wants to use this new treatment, Guardant’s test helps figure out who should actually get it.
Why this matters
This is the kind of approval investors like because it makes the product more useful in the real world, not just in a brochure. Companion diagnostics can become part of the treatment workflow, which can mean more test volume and a stronger moat for Guardant’s liquid biopsy business.
The business angle
Guardant isn’t just selling a test here — it’s embedding itself into the cancer-care decision tree. That’s a much better seat at the table than being the lab that gets called after everyone else has already picked dinner.
- The FDA approval supports Guardant360 CDx in a specific treatment setting
- HERNEXEOS is the first targeted therapy option for this patient group
- More labeled use cases can help deepen adoption among oncologists and health systems
Big picture: approvals like this won’t always light up the stock on their own, but they keep building the case that Guardant’s platform is becoming a more important part of precision oncology.